Virbac : CA T1 2024 : dans le haut des attentes et au-dessus de la trajectoire guidée
>T1 : +9,7% organique (vs +4,9% en FY 2023) - Le CA T1 ressort à 345,7 M€, soit +9,8% (+10,8% à tcc.). Par espèce, les animaux de compagnie sont en forte progression de 16.2% à ptcc et les animaux d’élevage affichent une croissance de 4,1% à tcc (+1,2% à ptcc). L’Europe affiche une croissance de 12,5% à tcc notamment portée par de solides performances en Europe Centrale et de l’Est (+34,9% à tcc) et en Europe du Nord (+23,8% à tcc). Les USA affichent la plus fort...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.